top of page
Search

Mursla invited to present at the Festival of Genomics and Biodata

Cambridge, UK, 18th January 2023: Mursla’s Chief Technology Officer, Dr. Tomás Dias, will present our latest insights on EV/exosome biology, EV multi-omics cargo and how Mursla’s cutting edge work is delivering next generation liquid biopsy solutions to clinics. Mursla is the only startup to be invited.


The Festival of Genomics and Biodata is the world’s largest genomics event. It exhibits industry leaders discussing the latest research, clinical breakthroughs and cutting-edge technologies. It is attended by over 2,000 people and includes keynote speakers such as the Chief Scientific Officer of NHS England or Professor Brian Cox.


Liquid biopsy is an emerging non-invasive method of detecting cancer with a blood draw instead of a tissue biopsy. Extracellular vesicles (EVs), including exosomes, are enriched in multiomics information mirroring their parental cells and can be sampled via a blood draw, enabling the convenient liquid biopsy of the tissue they originate from.


Dr. Dias’ presentation will be held on Thursday 26th of January 2023 at 11:30. This presentation is facilitated by our sponsor Perkin Elmer, a large healthcare and diagnostic solution provider.

-ENDS-

Contact: Mursla

Sarah Brereton, Director, Limewash

Tel: 07796 583 223

Email: sarah@limewash.co.uk


Notes to Editors


About Mursla

Mursla is a breakthrough exosome characterisation company based on a novel proprietary technology platform, ExoPheno™, which detects the multi-omics cargo of tissue-specific exosomes in blood for various biomedical applications. Exosomes (also known as Extracellular Vesicles) have been shown to reflect the state of their cellular sources, transporting specific ‘-omics’ information (DNA, RNA, proteins, lipids and metabolites) either locally or to distant sites via the circulatory system, including blood.


Discover more: mursla.com

bottom of page